BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaur R, Mehan S, Singh S. Understanding multifactorial architecture of Parkinson's disease: pathophysiology to management. Neurol Sci 2019;40:13-23. [PMID: 30267336 DOI: 10.1007/s10072-018-3585-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Khadzieva KI, Chernikova IV, Milyutina NP, Plotnikov AA. [Clinical and biochemical heterogeneity of Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:80-5. [PMID: 33459545 DOI: 10.17116/jnevro202012012180] [Reference Citation Analysis]
2 Marsman A, Lind A, Petersen ET, Andersen M, Boer VO. Prospective frequency and motion correction for edited 1H magnetic resonance spectroscopy. Neuroimage 2021;233:117922. [PMID: 33662573 DOI: 10.1016/j.neuroimage.2021.117922] [Reference Citation Analysis]
3 Zhu Y, Zhu X, Zhou Y, Zhang D. Reduced serum SIRT1 levels in patients with Parkinson's disease: a cross-sectional study in China. Neurol Sci 2021;42:1835-41. [PMID: 32909152 DOI: 10.1007/s10072-020-04711-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ciobanu AM, Ionita I, Buleandra M, David IG, Popa DE, Ciucu AA, Budisteanu M. Current advances in metabolomic studies on non-motor psychiatric manifestations of Parkinson's disease (Review). Exp Ther Med 2021;22:1010. [PMID: 34345292 DOI: 10.3892/etm.2021.10443] [Reference Citation Analysis]
5 See WZC, Naidu R, Tang KS. Cellular and Molecular Events Leading to Paraquat-Induced Apoptosis: Mechanistic Insights into Parkinson’s Disease Pathophysiology. Mol Neurobiol. [DOI: 10.1007/s12035-022-02799-2] [Reference Citation Analysis]
6 Chen P, Wang Y, Chen L, Song N, Xie J. Apelin-13 Protects Dopaminergic Neurons against Rotenone-Induced Neurotoxicity through the AMPK/mTOR/ULK-1 Mediated Autophagy Activation. Int J Mol Sci 2020;21:E8376. [PMID: 33171641 DOI: 10.3390/ijms21218376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Momtaz S, Memariani Z, El-Senduny FF, Sanadgol N, Golab F, Katebi M, Abdolghaffari AH, Farzaei MH, Abdollahi M. Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases. Front Physiol 2020;11:361. [PMID: 32411012 DOI: 10.3389/fphys.2020.00361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Saleem U, Raza Z, Anwar F, Chaudary Z, Ahmad B. Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson's disease. BMC Complement Altern Med 2019;19:352. [PMID: 31805998 DOI: 10.1186/s12906-019-2772-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
9 Pan L, Meng L, He M, Zhang Z. Tau in the Pathophysiology of Parkinson's Disease. J Mol Neurosci 2021. [PMID: 33459970 DOI: 10.1007/s12031-020-01776-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Scuderi SA, Ardizzone A, Paterniti I, Esposito E, Campolo M. Antioxidant and Anti-inflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases. Antioxidants (Basel) 2020;9:E630. [PMID: 32708926 DOI: 10.3390/antiox9070630] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
11 Trombetta-Lima M, Sabogal-Guáqueta AM, Dolga AM. Mitochondrial dysfunction in neurodegenerative diseases: A focus on iPSC-derived neuronal models. Cell Calcium 2021;94:102362. [PMID: 33540322 DOI: 10.1016/j.ceca.2021.102362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Akanji MA, Rotimi DE, Elebiyo TC, Awakan OJ, Adeyemi OS. Redox Homeostasis and Prospects for Therapeutic Targeting in Neurodegenerative Disorders. Oxid Med Cell Longev 2021;2021:9971885. [PMID: 34394839 DOI: 10.1155/2021/9971885] [Reference Citation Analysis]
13 Barroso SDS, Lopes LES, Santos KS, Gomes MZ. Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias. Expert Opinion on Therapeutic Patents 2019;29:979-85. [DOI: 10.1080/13543776.2019.1690453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Fu J, Peng L, Tao T, Chen Y, Li Z, Li J. Regulatory roles of the miR-200 family in neurodegenerative diseases. Biomed Pharmacother 2019;119:109409. [PMID: 31518873 DOI: 10.1016/j.biopha.2019.109409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Di Stefano A, Marinelli L, Eusepi P, Ciulla M, Fulle S, Di Filippo ES, Magliulo L, Di Biase G, Cacciatore I. Synthesis and Biological Evaluation of Novel Selenyl and Sulfur-l-Dopa Derivatives as Potential Anti-Parkinson's Disease Agents. Biomolecules 2019;9:E239. [PMID: 31216771 DOI: 10.3390/biom9060239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Federico A. Brain Awareness Week, CoVID-19 infection and Neurological Sciences. Neurol Sci 2020;41:747-8. [PMID: 32180157 DOI: 10.1007/s10072-020-04338-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
17 Kim JH, Lee HS, Ahn JH, Oh JK, Chang IB, Song JH, Wee JH, Min CY, Yoo DM, Choi HG. Association Between Thyroid Diseases and Parkinson's Disease: A Nested Case-Control Study Using a National Health Screening Cohort. J Parkinsons Dis 2021;11:211-20. [PMID: 33104041 DOI: 10.3233/JPD-202265] [Reference Citation Analysis]
18 Singh SS, Rai SN, Birla H, Zahra W, Rathore AS, Dilnashin H, Singh R, Singh SP. Neuroprotective Effect of Chlorogenic Acid on Mitochondrial Dysfunction-Mediated Apoptotic Death of DA Neurons in a Parkinsonian Mouse Model. Oxid Med Cell Longev 2020;2020:6571484. [PMID: 32566093 DOI: 10.1155/2020/6571484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
19 Cordaro M, Cuzzocrea S, Crupi R. An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events. Antioxidants (Basel) 2020;9:E216. [PMID: 32150935 DOI: 10.3390/antiox9030216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
20 Ou CY, He YH, Sun Y, Yang L, Shi WX, Li SJ. Effects of Sub-Acute Manganese Exposure on Thyroid Hormone and Glutamine (Gln)/Glutamate (Glu)-γ- Aminobutyric Acid (GABA) Cycle in Serum of Rats. Int J Environ Res Public Health 2019;16:E2157. [PMID: 31216744 DOI: 10.3390/ijerph16122157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Lestón Pinilla L, Ugun-Klusek A, Rutella S, De Girolamo LA. Hypoxia Signaling in Parkinson's Disease: There Is Use in Asking "What HIF?". Biology (Basel) 2021;10:723. [PMID: 34439955 DOI: 10.3390/biology10080723] [Reference Citation Analysis]
22 Zhang J, Chen R, Shi F, Yang P, Sun K, Yang X, Jin Y. Genome-wide data mining to construct a competing endogenous RNA network and reveal the pivotal therapeutic targets of Parkinson's disease. J Cell Mol Med 2020. [PMID: 33325158 DOI: 10.1111/jcmm.16190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Mahan VL. Effects of lactate and carbon monoxide interactions on neuroprotection and neuropreservation. Med Gas Res 2021;11:158-73. [PMID: 34213499 DOI: 10.4103/2045-9912.318862] [Reference Citation Analysis]
24 Marino BLB, de Souza LR, Sousa KPA, Ferreira JV, Padilha EC, da Silva CHTP, Taft CA, Hage-Melim LIS. Parkinson's Disease: A Review from Pathophysiology to Treatment. Mini Rev Med Chem 2020;20:754-67. [PMID: 31686637 DOI: 10.2174/1389557519666191104110908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
25 Iranshahy M, Javadi B, Sahebkar A. Protective effects of functional foods against Parkinson's disease: A narrative review on pharmacology, phytochemistry, and molecular mechanisms. Phytother Res 2022. [PMID: 35244296 DOI: 10.1002/ptr.7425] [Reference Citation Analysis]
26 Shi X, Zheng J, Ma J, Wang Z, Sun W, Li M, Huang S, Hu S. Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson's disease. Neurol Sci 2021. [PMID: 34405296 DOI: 10.1007/s10072-021-05558-8] [Reference Citation Analysis]
27 Palasz E, Wysocka A, Gasiorowska A, Chalimoniuk M, Niewiadomski W, Niewiadomska G. BDNF as a Promising Therapeutic Agent in Parkinson's Disease. Int J Mol Sci 2020;21:E1170. [PMID: 32050617 DOI: 10.3390/ijms21031170] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 25.5] [Reference Citation Analysis]
28 Khan I, Preeti K, Fernandes V, Khatri DK, Singh SB. Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders. Cell Mol Neurobiol 2021. [PMID: 33934227 DOI: 10.1007/s10571-021-01093-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]